Overview

Safety and Tolerability Clinical Trial of Different Doses of the Immunotherapeutic Drug Mobilan (M-VM3) and Placebo in Patients With Prostate Cancer

Status:
Completed
Trial end date:
2017-09-01
Target enrollment:
Participant gender:
Summary
Phase I single-blinded, randomized, placebo-controlled trial evaluating safety, tolerability, pharmacokinetics and pharmacodynamics of single injections of ascending doses of investigational drug product Mobilan (М-VM3) administered directly into the prostate of patients with prostate cancer.
Phase:
Phase 1
Details
Lead Sponsor:
Panacela Labs LLC